


Preclinical Development Handbook

ADME and
Biopharmaceutical
Properties

Edited by

Shayne Cox Gad



R969.1-62
p923

PRECLINICAL DEVELOPMENT HANDBOOK

ADME and Biopharmaceutical Properties

SHAYNE COX GAD, PH.D., D.A.B.T.

Gad Consulting Services
Cary, North Carolina



E2008001515

 **WILEY-INTERSCIENCE**

A JOHN WILEY & SONS, INC., PUBLICATION

Copyright © 2008 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com.

Library of Congress Cataloging-in-Publication Data is available.

ISBN: 978-0-470-24847-8

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

**PRECLINICAL
DEVELOPMENT
HANDBOOK**

**ADME and
Biopharmaceutical
Properties**

CONTRIBUTORS

Adegoke Adeniji, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, *Chemical and Physical Characterizations of Potential New Chemical Entity*

Adeboye Adjare, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, *Chemical and Physical Characterizations of Potential New Chemical Entity*

Zvia Agur, Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel; Optimata Ltd., Ramat-Gan, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*

Melvin E. Andersen, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, *Physiologically Based Pharmacokinetic Modeling*

Joseph P. Balthasar, University of Buffalo, The State University of New York, Buffalo, New York, *Pharmacodynamics*

Stelvio M. Bandiera, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, *Cytochrome P450 Enzyme*

Ihor Bekersky, Consultant, Antioch, Illinois, *Bioavailability and Bioequivalence Studies*

Marival Bermejo, University of Valencia, Valencia, Spain, *How and Where Are Drugs Absorbed?*

Jan H. Beumer, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, *Mass Balance Studies*

Prasad V. Bharatam, National Institute of Pharmaceutical Education and Research (NIPER), Nagar, India, *Modeling and Informatics in Drug Design*

- Deepa Bisht**, National JALMA Institute for Leprosy and Other Myobacterial Diseases, Agra, India, *Accumulation of Drugs in Tissues*
- Scott L. Childs**, SSCI, Inc., West Lafayette, Indiana, *Salt and Cocystal Form Selection*
- Harvel J. Clewell III**, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina, *Physiologically Based Pharmacokinetic Modeling*
- Brett A. Cowans**, SSCI, Inc., West Lafayette, Indiana, *Salt and Cocystal Form Selection*
- Dipankar Das**, University of Alberta, Edmonton, Alberta, Canada, *Protein-Protein Interactions*
- A. G. de Boer**, University of Leiden, Leiden, The Netherlands, *The Blood-Brain Barrier and Its Effect on Absorption and Distribution*
- Pankaj B. Desai**, University of Cincinnati Medical Center, Cincinnati, Ohio, *Data Analysis*
- Merrill J. Egorin**, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, *Mass Balance Studies*
- Julie L. Eiseman**, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, *Mass Balance Studies*
- Moran Elishmereni**, Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/ Toxicity Profile of Drugs: The Thrombocytopenia Case Study*
- Dora Farkas**, Tufts University School of Medicine, Boston, Massachusetts, *Mechanisms and Consequences of Drug-Drug Interactions*
- Sandrea M. Francis**, National Institute of Pharmaceutical Education and Research (NIPER), Nagar, India, *Modeling and Informatics in Drug Design*
- Shayne Cox Gad**, Gad Consulting Services, Cary, North Carolina, *Regulatory Requirements for INDs/FIH (First in Human) Studies*
- P.J. Gaillard**, to-BBB Technologies BV, Leiden, The Netherlands, *The Blood-Brain Barrier and Its Effect on Absorption and Distribution*
- Srinivas Ganta**, University of Auckland, Auckland, New Zealand, *Permeability Assessment*
- Sanjay Garg**, University of Auckland, Auckland, New Zealand, *Permeability Assessment*
- Isabel Gonzalez-Alvarez**, University of Valencia, Valencia, Spain, *How and Where Are Drugs Absorbed?*
- Eric M. Gorman**, The University of Kansas, Lawrence, Kansas, *Stability: Physical and Chemical*
- Luis Granero**, University of Valencia, Valencia, Spain, *Absorption of Drugs after Oral Administration*

- David J. Greenblatt**, Tufts University School of Medicine, Boston, Massachusetts, *Mechanisms and Consequences of Drug–Drug Interactions*
- Ken Grime**, AstraZeneca R&D Charnwood, Loughborough, United Kingdom, *Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions*
- William L. Hayton**, The Ohio State University, Columbus, Ohio, *Allometric Scaling*
- William W. Hope**, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, *Experimental Design Considerations in Pharmacokinetics Studies*
- Eugene G. Hrycay**, Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia, Canada, *Cytochrome P450 Enzymes*
- Teh-Min Hu**, National Defense Medical Center, Taipei, Taiwan, *Allometric Scaling*
- Subheet Jain**, Punjabi University, Patiala, Punjab, India, *Dissolution*
- Izet M. Kapetanovic**, NIH NCI Division of Cancer Prevention, Chemoprevention Agent Development Research Group, Bethesda, Maryland, *Analytical Chemistry Methods: Developments and Validation*
- Kamaljit Kaur**, University of Alberta, Edmonton, Alberta, Canada, *Protein–Protein Interactions*
- Jane R. Kenny**, AstraZeneca R&D Charnwood, Loughborough, United Kingdom, *Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions*
- Masood Khan**, Covance Laboratories Inc., Immunochemistry Services, Chantilly, Virginia, *Method Development for Preclinical Bioanalytical Support*
- Smriti Khanna**, National Institute of Pharmaceutical Education and Research (NIPER), Nagar, India, *Modeling and Informatics in Drug Design*
- Yuri Kheifetz**, Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*
- Yuri Kogan**, Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*
- Niels Krebsfaenger**, Schwarz Biosciences, Monheim, Germany, *Species Comparison of Metabolism in Microsomes and Hepatocytes*
- Thierry Lave**, F. Hoffman-LaRoche Ltd., Basel, Switzerland, *Physiologically Based Pharmacokinetic Modeling*
- Albert P. Li**, In Vitro ADMET Laboratories, Inc., Columbia, Maryland, *In Vitro Evaluation of Metabolic Drug–Drug Interactions: Scientific Concepts and Practical Considerations*

- Charles W. Locuson**, University of Minnesota, Minneapolis, Minnesota, *Metabolism Kinetics*
- Alexander V. Lyubimov**, University of Illinois at Chicago, Chicago, Illinois, *Analytical Chemistry Methods: Developments and Validation; Dosage Formulation; Bioavailability and Bioequivalence Studies*
- Dermot F. McGinnity**, AstraZeneca R&D Charnwood, Loughborough, United Kingdom, *Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions*
- Peter Meek**, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, *Computer Techniques: Identifying Similarities Between Small Molecules*
- Donald W. Miller**, University of Manitoba, Winnipeg, Manitoba, Canada, *Transporter Interactions in the ADME Pathway of Drugs*
- Mehran F. Moghaddam**, Celegne, San Diego, California, *Metabolite Profiling and Structural Identification*
- Guillermo Moyna**, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, *Computer Techniques: Identifying Similarities Between Small Molecules*
- Eric J. Munson**, The University of Kansas, Lawrence, Kansas, *Stability: Physical and Chemical*
- Ann W. Newman**, SSCI, Inc., West Lafayette, Indiana, *Salt and Cocrystal Form Selection*
- Mohammad Owais**, Aligarh Muslim University, Aligarh, India, *Accumulation of Drugs in Tissues*
- Brian E. Padden**, Schering-Plough Research Institute, Summit, New Jersey, *Stability: Physical and Chemical*
- Sree D. Panuganti**, Purdue University, West Lafayette, Indiana, *Drug Clearance*
- Jayanth Panyam**, University of Minnesota, Minneapolis, Minnesota, *Distribution: Movement of Drugs through the Body*
- Yogesh Patil**, Wayne State University, Detroit, Michigan, *Distribution: Movement of Drugs through the Body*
- James W. Paxton**, The University of Auckland, Auckland, New Zealand, *Interrelationship between Pharmacokinetics and Metabolism*
- Olavi Pelkonen**, University of Oulu, Oulu, Finland, *In Vitro Metabolism in Preclinical Drug Development*
- Vidmantas Petraitis**, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, *Experimental Design Considerations in Pharmacokinetics Studies*
- Ana Polache**, University of Valencia, Valencia, Spain, *Absorption of Drugs after Oral Administration*

- Elizabeth R. Rayburn**, University of Alabama at Birmingham, Birmingham, Alabama, *Linkage Between Toxicology of Drugs and Metabolism*
- Micaela B. Reddy**, Roche Palo Alto LLC, Palo Alto, California, *Physiologically Based Pharmacokinetic Modeling*
- Robert J. Riley**, AstraZeneca R&D Charnwood, Loughborough, United Kingdom, *Utilization of In Vitro Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions*
- Sevim Rollas**, Marmara University, Istanbul, Turkey, *In Vivo Metabolism in Pre-clinical Drug Development*
- Bharti Sapra**, Punjabi University, Patiala, Punjab, India, *Dissolution*
- Richard I. Shader**, Tufts University School of Medicine, Boston, Massachusetts, *Mechanisms and Consequences of Drug–Drug Interactions*
- Dhaval Shah**, University of Buffalo, The State University of New York, Buffalo, New York, *Pharmacodynamics*
- Puneet Sharma**, University of Auckland, Auckland, New Zealand, *Permeability Assessment*
- Beom Soo Shin**, University of Buffalo, The State University of New York, Buffalo, New York, *Pharmacodynamics*
- Meir Shoham**, Optimata Ltd., Ramat-Gan, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*
- Mavanur R. Suresh**, University of Alberta, Edmonton, Alberta, Canada, *Protein–Protein Interactions*
- Craig K. Svensson**, Osmetech Molecular Diagnostics, Pasadena, California, *Drug Clearance*
- A. K. Tiwary**, Punjabi University, Patiala, Punjab, India, *Dissolution*
- Ari Tolonen**, Novamass Analytical Ltd., Oulu, Finland; University of Oulu, Oulu, Finland, *In Vitro Metabolism in Preclinical Drug Development*
- Timothy S. Tracy**, University of Minnesota, Minneapolis, Minnesota, *Metabolism Kinetics*
- Miia Turpeinen**, University of Oulu, Oulu, Finland, *In Vitro Metabolism in Preclinical Drug Development*
- Jouko Uusitalo**, Novamass Analytical Ltd., Oulu, Finland, *In Vitro Metabolism in Preclinical Drug Development*
- Vladimir Vainstein**, Institute for Medical Biomathematics (IMBM), Bene-Ataroth, Israel; Optimata Ltd., Ramat-Gan, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*

Krishnamurthy Venkatesan, National JALMA Institute for Leprosy and Other Myobacterial Diseases, Agra, India, *Accumulation of Drugs in Tissues*

Lisa L. von Moltke, Tufts University School of Medicine, Boston, Massachusetts, *Mechanisms and Consequences of Drug-Drug Interactions*

Jayesh Vora, PRTM Management Consultants, Mountain View, California, *Data Analysis*

Thomas J. Walsh, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, *Experimental Design Considerations in Pharmacokinetics Studies*

Naidong Weng, Johnson & Johnson Pharmaceutical Research & Development, Bioanalytical Department, Raritan, New Jersey, *Method Development for Pre-clinical Bioanalytical Support*

Randy Zauhar, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania, *Computer Techniques: Identifying Similarities Between Small Molecules*

Ruiwen Zhang, University of Alabama at Birmingham, Birmingham, Alabama, *Linkage Between Toxicology of Drugs and Metabolism*

Yan Zhang, Drug Metabolism and Biopharmaceutics, Incyte Corporation, Wilmington, Delaware, *Transporter Interactions in the ADME Pathway of Drugs*

Irit Ziv, Optimata Ltd., Ramat-Gan, Israel, *Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study*

PREFACE

This *Preclinical Development Handbook: ADME and Biopharmaceutical Properties* continues and extends the objective behind the entire *Handbook* series: an attempt to achieve a through overview of the current and leading-edge nonclinical approaches to evaluating the pharmacokinetic and pharmacodynamic aspects of new molecular entity development for therapeutics. The 38 chapters cover the full range of approaches to understanding how new molecules are absorbed and distributed in model systems, have their biologic effects, and then are metabolized and excreted. Such evaluations provide the fundamental basis for making decisions as to the possibility and means of pursuing clinical development of such moieties. Better performance in this aspect of the new drug development process is one of the essential keys to both shortening and increasing the chance of success in developing new drugs.

The volume is unique in that it seeks to cover the entire range of available approaches to understanding the performance of a new molecular entity in as broad a manner as possible while not limiting itself to a superficial overview. Thanks to the persistent efforts of Mindy Myers and Gladys Mok, these 38 chapters, which are written by leading practitioners in each of these areas, provide coverage of the primary approaches to the problems of understanding the mechanisms that operate in *in vivo* systems to transfer a drug to its site of action and out.

I hope that this newest addition to our scientific banquet is satisfying and useful to all those practitioners working in or entering the field.

CONTENTS

Preface	xv
1 Modeling and Informatics in Drug Design <i>Prasad V. Bharatam, Smriti Khanna, and Sandra M. Francis</i>	1
2 Computer Techniques: Identifying Similarities Between Small Molecules <i>Peter Meek, Guillermo Moyna, and Randy Zauhar</i>	47
3 Protein-Protein Interactions <i>Kamaljit Kaur, Dipankar Das, and Mavanur R. Suresh</i>	87
4 Method Development for Preclinical Bioanalytical Support <i>Masood Khan and Naidong Weng</i>	117
5 Analytical Chemistry Methods: Developments and Validation <i>Izet M. Kapetanovic and Alexander V. Lyubimov</i>	151
6 Chemical and Physical Characterizations of Potential New Chemical Entity <i>Adegoke Adeniji and Adeboye Adejare</i>	211
7 Permeability Assessment <i>Srinivas Ganta, Puneet Sharma, and Sanjay Garg</i>	227
8 How and Where Are Drugs Absorbed? <i>Marival Bermejo and Isabel Gonzalez-Alvarez</i>	249
9 Absorption of Drugs after Oral Administration <i>Luis Granero and Ana Polache</i>	281
	xi

10	Distribution: Movement of Drugs through the Body	323
	<i>Jayanth Panyam and Yogesh Patil</i>	
11	The Blood–Brain Barrier and Its Effect on Absorption and Distribution	353
	<i>A. G. de Boer and P. J. Gaillard</i>	
12	Transporter Interactions in the ADME Pathway of Drugs	407
	<i>Yan Zhang and Donald W. Miller</i>	
13	Accumulation of Drugs in Tissues	429
	<i>Krishnamurthy Venkatesan, Deepa Bisht, and Mohammad Owais</i>	
14	Salt and Cocrystal Form Selection	455
	<i>Ann W. Newman, Scott L. Childs, and Brett A. Cowans</i>	
15	Dissolution	483
	<i>A.K. Tiwary, Bharti Sapra, and Subheet Jain</i>	
16	Stability: Physical and Chemical	545
	<i>Eric M. Gorman, Brian E. Padden, and Eric J. Munson</i>	
17	Dosage Formulation	571
	<i>Alexander V. Lyubimov</i>	
18	Cytochrome P450 Enzymes	627
	<i>Eugene G. Hrycay and Stelvio M. Bandiera</i>	
19	Metabolism Kinetics	697
	<i>Charles W. Locuson and Timothy S. Tracy</i>	
20	Drug Clearance	715
	<i>Sree D. Panuganti and Craig K. Svensson</i>	
21	<i>In Vitro</i> Metabolism in Preclinical Drug Development	743
	<i>Olavi Pelkonen, Ari Tolonen, Miia Turpeinen, and Jouko Uusitalo</i>	
22	Utilization of <i>In Vitro</i> Cytochrome P450 Inhibition Data for Projecting Clinical Drug–Drug Interactions	775
	<i>Jane R. Kenny, Dermot F. McGinnity, Ken Grime, and Robert J. Riley</i>	
23	<i>In Vivo</i> Metabolism in Preclinical Drug Development	829
	<i>Sevim Rollas</i>	
24	<i>In Vitro</i> Evaluation of Metabolic Drug–Drug Interactions: Scientific Concepts and Practical Considerations	853
	<i>Albert P. Li</i>	
25	Mechanisms and Consequences of Drug–Drug Interactions	879
	<i>Dora Farkas, Richard I. Shader, Lisa L. von Moltke, and David J. Greenblatt</i>	
26	Species Comparison of Metabolism in Microsomes and Hepatocytes	919
	<i>Niels Krebsfaenger</i>	

27	Metabolite Profiling and Structural Identification	937
	<i>Mehran F. Moghaddam</i>	
28	Linkage between Toxicology of Drugs and Metabolism	975
	<i>Ruiwen Zhang and Elizabeth R. Rayburn</i>	
29	Allometric Scaling	1009
	<i>William L. Hayton and Teh-Min Hu</i>	
30	Interrelationship between Pharmacokinetics and Metabolism	1037
	<i>James W. Paxton</i>	
31	Experimental Design Considerations in Pharmacokinetic Studies	1059
	<i>William W. Hope, Vidmantas Petraitis, and Thomas J. Walsh</i>	
32	Bioavailability and Bioequivalence Studies	1069
	<i>Alexander V. Lyubimov and Ihor Bekersky</i>	
33	Mass Balance Studies	1103
	<i>Jan H. Beumer, Julie L. Eiseman, and Merrill J. Egorin</i>	
34	Pharmacodynamics	1133
	<i>Beom Soo Shin, Dhaval Shah, and Joseph P. Balthasar</i>	
35	Physiologically Based Pharmacokinetic Modeling	1167
	<i>Harvey J. Clewell III, Micaela B. Reddy, Thierry Lave, and Melvin E. Andersen</i>	
36	Mathematical Modeling as a New Approach for Improving the Efficacy/Toxicity Profile of Drugs: The Thrombocytopenia Case Study	1229
	<i>Zvia Agur, Moran Elishmereni, Yuri Kogan, Yuri Kheifetz, Irit Ziv, Meir Shoham, and Vladimir Vainstein</i>	
37	Regulatory Requirements for INDs/FIH (First in Human) Studies	1267
	<i>Shayne Cox Gad</i>	
38	Data Analysis	1309
	<i>Jayesh Vora and Pankaj B. Desai</i>	
	Index	1323

MODELING AND INFORMATICS IN DRUG DESIGN

PRASAD V. BHARATAM,* SMRITI KHANNA, AND SANDREA M. FRANCIS
National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar, India

Contents

- 1.1 Introduction
- 1.2 Computational Chemistry
 - 1.2.1 *Ab Initio* Quantum Chemical Methods
 - 1.2.2 Semiempirical Methods
 - 1.2.3 Molecular Mechanical Methods
 - 1.2.4 Energy Minimization and Geometry Optimization
 - 1.2.5 Conformational Analysis
- 1.3 Computational Biology
 - 1.3.1 *Ab Initio* Structure Prediction
 - 1.3.2 Homology Modeling
 - 1.3.3 Threading or Remote Homology Modeling
- 1.4 Computational Medicinal Chemistry
 - 1.4.1 Quantitative Structure–Activity Relationship (QSAR)
 - 1.4.2 Pharmacophore Mapping
 - 1.4.3 Molecular Docking
 - 1.4.4 *De Novo* Design
- 1.5 Pharmacoinformatics
 - 1.5.1 Chemoinformatics
 - 1.5.2 Bioinformatics
 - 1.5.3 Virtual Screening
 - 1.5.4 Neuroinformatics
 - 1.5.5 Immunoinformatics
 - 1.5.6 Drug Metabolism Informatics
 - 1.5.7 Toxicoinformatics
 - 1.5.8 Cancer Informatics
- 1.6 Future Scope
- References

**Corresponding author.*

Preclinical Development Handbook: ADME and Biopharmaceutical Properties,
edited by Shayne Cox Gad
Copyright © 2008 John Wiley & Sons, Inc.

1.1 INTRODUCTION

Modeling and informatics have become indispensable components of rational drug design (Fig. 1.1). For the last few years, chemical analysis through molecular modeling has been very prominent in computer-aided drug design (CADD). But currently modeling and informatics are contributing in tandem toward CADD. Modeling in drug design has two facets: modeling on the basis of knowledge of the drugs/leads/ligands often referred to as ligand-based design and modeling based on the structure of macromolecules often referred to as receptor-based modeling (or structure-based modeling). Computer-aided drug design is a topic of medicinal chemistry, and before venturing into this exercise one must employ computational chemistry methods to understand the properties of chemical species, on the one hand, and employ computational biology techniques to understand the properties of biomolecules on the other. Information technology is playing a major role in decision making in pharmaceutical sciences. Storage, retrieval, and analysis of data of chemicals/biochemicals of therapeutic interest are major components of pharmacoinformatics. Quite




FIGURE 1.1 A schematic diagram showing a flowchart of activities in computer aided drug development. The figure shows that the contributions from modeling methods and informatics methods toward the drug development are parallel and in fact not really distinguishable.

often, the efforts based on modeling and informatics get thoroughly integrated with each other, as in the case of virtual screening exercises. In this chapter, the molecular modeling methods that are in vogue in the fields of (1) computational chemistry, (2) computational biology, (3) computational medicinal chemistry, and (4) pharmacoinformatics are presented and the resources available in these fields are discussed.

1.2 COMPUTATIONAL CHEMISTRY

Two-dimensional (2D) structure drawing and three-dimensional (3D) structure building are the important primary steps in computational chemistry for which several molecular visualization packages are available. The most popular of these are ChemDraw Ultra and Chem3D Pro, which are a part of the ChemOffice suite of software packages [1]. ACD/ChemSketch [2], MolSuite [3], and many more of this kind are other programs for the same purpose. Refinement has to be carried out on all the drawings and 3D structures so as to improve the chemical accuracy of the structure on the computer screen. Structure refinement based on heuristic rules/cleanup procedures is a part of all these software packages. However, chemical accuracy of the 3D structures still remains poor even after cleanup. Further refinement can be carried out by performing energy minimization using either molecular mechanical or quantum chemical procedures. By using these methods, the energy of a molecule can be estimated in any given state. Following this, with the help of first and second derivatives of energy, it can be ascertained whether the given computational state of the molecules belongs to a chemically acceptable state or not. During this process, the molecular geometry gets modified to a more appropriate, chemically meaningful state – the entire procedure is known as geometry optimization. The geometry optimized 3D structure is suitable for property estimation, descriptor calculation, conformational analysis, and finally for drug design exercise [4–6].

1.2.1 Ab Initio Quantum Chemical Methods

Every molecule possesses internal energy (U), for the estimation of which quantum chemical calculations are suitable. Quantum chemical calculations involve rigorous mathematical derivations and attempt to solve the Schrödinger equation, which in its simplest form may be written as

$$H\Psi = E\Psi \quad (1.1)$$

$$\hat{H}_{\text{el}} = \sum_i \left(-\frac{1}{2} \nabla_i^2 \right) - \sum_i \sum_a \frac{Z_a}{|r_i - d_a|} + \frac{1}{2} \sum_i \sum_{j \neq i} \frac{1}{|r_i - r_j|} + \frac{1}{2} \sum_a \sum_{b \neq a} \frac{Z_a Z_b}{|d_a - d_b|} \quad (1.2)$$

where ψ represents the wavefunction, E represents energy, ∇ represents the kinetic energy operator for electrons, r_i defines the vector position of electron i with vector components in Bohr radii, Z_a is the charge of fixed nucleus a in units of the elementary charge, and d_a is the vector position of nucleus a with vector components in Bohr radii.